Dr John Rothman, Executive Vice President Science & Operations, Advaxis, joined us at the World Vaccine Congress Lyon 2012 to give details on the interim clinical results on the treatment of HPV induced neoplasia and carcinoma with a live attenuated Listeria immunotherapy.
Here is a taster of what you can discover from this presentation:
Listeria monocytogenes (Lm) based Lm-LLO Immunotherapies
â¢A simple concept: We are using a persistent, protective immune response to an attenuated bacteria; only our bacteria secretes tumor or other disease antigens.
-Live metabolically competent Listeria is more complex than antibodies or synthetic molecules and engenders a more compete immune response
â¢We are born with an immune response to Lm
-Pathogen Associated Molecular Patterns (PAMP)
-Non-pathogenic: attenuated 104 -105 times
-Secrete an antigen fused to a non-hemolytic, highly immunogenic truncated fragment of LLO
â¢Adds to native LLO, P60, Plc A & B, Flagellin, etc.
Interim clinical results on the treatment of HPV induced neoplasia and carcinoma with a live attenuated Listeria immunotherapy
Â· ADXS11-001 is currently in 5 phase 2 trials for the treatment of cervix cancer, head and neck cancer, anal cancer, and cervical dysplasia
Â· The agent has been well tolerated and has generated a strong efficacy signal
Â· Preliminary results observed thus far and future directions will be presented
Dr John Rothman, Executive Vice President Science & Operations, Advaxis
To learn more about this and the other topics discussed at this event, please click here >